Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Plus Etanercept vs Ruxolitinib Alone for Corticosteroid-Refractory Severe Acute GVHD
NCT07184853Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept in corticosteroid-refractory acute graft-versus-host disease (SR-aGVHD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall Response Rate at Day 28. Started Sep 2025; status: recruiting.
02
Drugs
etanercept
03
Conditions
corticosteroid-refractory acute graft-versus-host disease (SR-aGVHD)
Beyond the preview
Go deeper on NCT07184853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184853.